Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nader Fotouhi

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2013
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapyYong S Chang, Bradford Graves, Vincent Guerlavais, et al.
Science Advances|March 15, 2024
Redirecting raltitrexed from cancer cell thymidylate synthase to <i>Mycobacterium tuberculosis</i> phosphopantetheinyl transferaseAmrita Singh, Samantha Ottavi, Inna Krieger, et al.
Cell|February 24, 2023
Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agentsJidong Zhang, Christine Lair, Christine Roubert, et al.
Antimicrobial Agents and Chemotherapy|May 24, 2022
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective <i>In Vivo</i> with the Potential To Shorten Tuberculosis TreatmentEric L Nuermberger, Maria Santos Martínez-Martínez, Olalla Sanz, et al.
Journal of Medicinal Chemistry|April 13, 2010
Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1Robert A Goodnow, Alexandra Hicks, Achyutharao Sidduri, et al.
Prostaglandins & Other Lipid Mediators|March 11, 2010
Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primatesAlexandra Hicks, Robert Goodnow, Gary Cavallo, et al.
Nature Communications|October 11, 2022
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugsSimon R Green, Susan H Davis, Sebastian Damerow, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2013
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapyYong S Chang, Bradford Graves, Vincent Guerlavais, et al.
Science Advances|March 15, 2024
Redirecting raltitrexed from cancer cell thymidylate synthase to <i>Mycobacterium tuberculosis</i> phosphopantetheinyl transferaseAmrita Singh, Samantha Ottavi, Inna Krieger, et al.
Cell|February 24, 2023
Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agentsJidong Zhang, Christine Lair, Christine Roubert, et al.
Antimicrobial Agents and Chemotherapy|May 24, 2022
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective <i>In Vivo</i> with the Potential To Shorten Tuberculosis TreatmentEric L Nuermberger, Maria Santos Martínez-Martínez, Olalla Sanz, et al.
Journal of Medicinal Chemistry|April 13, 2010
Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1Robert A Goodnow, Alexandra Hicks, Achyutharao Sidduri, et al.
Prostaglandins & Other Lipid Mediators|March 11, 2010
Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primatesAlexandra Hicks, Robert Goodnow, Gary Cavallo, et al.
Nature Communications|October 11, 2022
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugsSimon R Green, Susan H Davis, Sebastian Damerow, et al.
Pageof 4